ATYR insider buying and SEC filings, explained
aTYR PHARMA INC · CIK 1339970
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Company profile
- Exchanges
- Nasdaq
- Industry (SIC)
- Biological Products, (No Diagnostic Substances)
- State of incorporation
- DE
- Fiscal year end
- Dec 31
Insider activity in the last 12 months
Bought
$50K
Insiders who bought
1
Sold (not marked 10b5-1)
$6K
Planned sales (10b5-1)
$0
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| May 27, 2026 | Purchase (code P) | Paul Schimmel (Director) bought 100,000 shares indirectly at about $0.5000 ($50K), reported as a purchase (code P). Indirect holdings up 15% to 779,143 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed May 28, 2026 |
| Feb 4, 2026 | Sale | Sanjay Shukla (CEO and Director) sold 3,745 shares at $0.9800 ($4K). Holdings down 2% to 153,553 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 4, 2026 |
| Feb 4, 2026 | Sale | Jill Marie Broadfoot (CFO) sold 1,558 shares at $0.9800 ($2K). Holdings down 4% to 37,296 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 4, 2026 |
| Feb 4, 2026 | Sale | Nancy Denyes (General Counsel) sold 1,118 shares at $0.9800 ($1K). Holdings down 3% to 33,124 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 4, 2026 |
13 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow ATYR in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.